Poor Performance Continues in Nucleus Software
Hopefully recovers soon
Con-call Highlights -
Nucleus Software Q1 FY 2024-25 Earnings Call Key Takeaways
Financial Performance:
- Consolidated revenue: Rs. 195.4 crore
- Consolidated EBIDTA: Rs. 28.8 crore
- Consolidated PAT: Rs. 30.2 crore
- Consolidated EPS: Rs. 11.3
- Standalone revenue: Rs. 181.7 crore
- Standalone PAT: Rs. 31.2 crore
- Standalone EPS: Rs. 11.6
- Order book: Rs. 813.4 crore
- Cash and cash equivalent as of June 30, 2024: Rs. 920.8 crore
Operational Performance:
- Added 62 employees during the quarter
- Revenue mix: 58% domestic, 42% international
- No customer losses due to repricing initiatives
- Repricing progress slower than anticipated
- New customer acquisition yielded no revenue in the last quarter
- Long lead times for new implementations due to pricing complexity
Future Outlook:
- Management expressed confidence in bouncing back financially in coming quarters - Continued focus on product licensing and cloud-based services
- Plans to onboard sales leaders in different regions
Concerns:
- Decline in topline and bottom line performance
- Stagnant revenue growth
- Repricing initiative facing challenges
Other Important Points:
- Long-term focus over short-term fluctuations
- Committed to retaining top industry talent
- Exploring dividend payout and buyback options
- New product developments include an Islamic version of FinnOne Neo for the Middle East and Malaysia
Buyback meeting to be held on 22nd August, 2024 :
Link : https://www.bseindia.com/xml-data/corpfiling/AttachLive/020560ba-1ebf-457d-8011-2fde31fca0ef.pdf
Not directly related to the fundamentals of Nucleus; wanted to work out the meaning of āNon-institutional investorā in a buyback.
Hereās the NSE demand schedule - https://www.nseindia.com/market-data/tender-issue-information?symbol=NUCLEUS&type=Active
Under ābid detailsā, do the NIIs categorized as āothersā mean ordinary investors having shares worth > 200,000 in their demat account on the cutoff date, or they get clubbed with retail investors, and NIIs mean something else?
Now completely off-topic - this was the last buyback before Oct 1 where buyback-flippers had a chance to make real money. Post Oct 1, buyback proceeds will get treated as dividend, and get taxed according to oneās slab, while providing for acquisiton costs to be treated as a capital loss.
Positives:
- Nucleus releases a new module/update every year increasing value of product
- Being in fixed price contracts, the price escalations take time while wage inflation impacts EBITDA margins
- The contracts are usually 3-7 years long, with repricing followed at the end of the life
- Considering 2022 as the year of reprising and low EBITDA margins due to āThe Great Resignationā, the same repricing can be considered to occur from 2025 to 2029
- The price charts reflect this growth over past 15 years with a flat to downward trend followed by a lumpy growth period
- ~Rs 500 crores of cash is 16.67% of the MV with no debt, allows for a downside safety in current market conditions
- The company has de-risked its business in terms of customer concentration, dependence on export sales, etc
Negatives:
- The CFO is low considering this being a tech company as the receivables is high, and the CFO could have been increased by using working capital
- The working capital to increase CFO will increase valuations and improve cost of capital, but the company is debt averse and holds cash
- The foreign subsidiaries do not make CFO as can be seen in their reported financials
- The company is dependent on BFSI doing well along with IT, both being neglected by the market
- Promoter selling stake in recent buyback, which is understandable by the fact that the promoter stake is very close to 75%. Arun Jain in non-promoter can be considered a promoter since he is with the company since 1990s. Therefore total stake is 74.3% which should come down after buyback
All-in-all, if the company is available at a good PE can purchase and hold for 4-5 years (2029) to see returns
Just will add another point regarding their new product in upcoming Co-Lending space.
Considering Nucleus reputation with their clients and future of Co Lending, I see this as a good growth handle along with Nucleus efforts to penetrate new global territories.
Current PE of 20 is lucrative and I am betting on a re-rating similar to Oracle Finance.
Although no direct comparison but I feel limited downside and a regular cash generating company with only organic growth is a slow and consistent compounder.